Overview

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

Status:
RECRUITING
Trial end date:
2027-10-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion
Phase:
PHASE1
Details
Lead Sponsor:
BeiGene
Treatments:
Drug Therapy